Golotimod - CAS 229305-39-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Golotimod is an orally bioavailable synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential immunostimulating, antimicrobial and antineoplastic activities. Although the exact mechanism of action is unknown, golotimod appears to inhibit the expression of STAT-3, reversing immunosuppression and stimulating an anti-tumor immune response. This agent may stimulate the production of T-lymphocytes (in particular the helper T [Th1] cells), activate macrophages, and increase levels of interleukin 2 and interferon gamma. STAT-3, a transcription factor upregulated in many cancer cell types, is involved in tumor cell growth and survival and immunosuppression.
Publictions citing BOC Sciences Products
  • >> More
white solid powder
SCV 07; gamma-D-glutamyl-L-tryptophan.
Current Developer:
SciClone Pharmaceuticals
1.Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07).
Watkins B1, Pouliot K, Fey E, Tuthill C, Sonis S. Oral Dis. 2010 Oct;16(7):655-60. doi: 10.1111/j.1601-0825.2010.01671.x.
OBJECTIVE: To evaluate the efficacy of a novel immunomodulating peptide (SCV-07) in attenuating the course of radiation-induced mucositis in an established animal model of oral mucositis (OM).
2.Discontinued drugs in 2012 - 2013: hepatitis C virus infection.
Gentile I1, Buonomo AR, Zappulo E, Borgia G. Expert Opin Investig Drugs. 2015 Feb;24(2):239-51. doi: 10.1517/13543784.2015.982274. Epub 2014 Nov 11.
INTRODUCTION: Hepatitis C virus (HCV) chronically infects about 150 million people worldwide. Antiviral treatment can stop and even reverse the progression of the disease. Several antivirals have been developed. However, about 10,000 compounds are tested for each drug that eventually reaches the market. It would be useful to learn from these failures, for example, by reporting the candidate drugs that were discontinued and the reason for discontinuation.
3.SCV-07 (SciClone Pharmaceuticals/Verta).
Aspinall RJ1, Pockros PJ. Curr Opin Investig Drugs. 2006 Feb;7(2):180-5.
SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 229305-39-9 Golotimod

Quick Inquiry

Verification code

Featured Items